Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

FluoroPharma Medical, Inc. (FPMI) Addresses Heart Disease With Unmatched Proprietary Products

In the marketplace, the principal strength of FluoroPharma Medical, developer of tracer agents for use with positron emission tomography (PET), is the uniqueness and effectiveness of their products. Their chemical agents, by highlighting certain biological processes in the body, allow PET technology to identify disease activity long before traditional symptoms appear. Their protected proprietary formulations offer clear advantages over competitor products, and, by focusing on the diagnosis of coronary artery disease (NYSEARCA:CAD), they address a major and largely unmet market need.

BFPET - FluoroPharma's novel blood flow imaging agent is for use in conjunction with stress testing for the detection of ischemic and infarcted tissue within the heart muscle tissue of patients having suspected or proven chronic CAD. It enters the myocardial cells of the heart muscle in direct proportion to blood flow and membrane potential - the two most important physiological indicators of adequate blood supply to the heart. Specifically, the company believes that certain damaged heart tissue can be more reliably detected using BFPET. If approved, BFPET will represent the first molecular imaging blood flow agent commercialized for use in the cardiovascular segment of the PET imaging market.

CardioPET - A unique molecular imaging agent, CardioPET is designed to assess myocardial metabolism for the detection of ischemic and infarcted tissue, including for patients unable to undergo stress testing, as well as for cardiac viability assessment to predict functional improvement for revascularization patients. CardioPET would represent the first imaging agent available in the U.S. for use in patients with acute and chronic CAD that cannot undergo stress-testing, and could have other operational advantages as well.

VasoPET - Designed to detect vulnerable coronary artery plaque in patients with CAD, VasoPET addresses a significant unmet clinical objective. If approved, it would represent the first PET cardiac product to reliably image inflamed plaque and therefore may differentiate between vulnerable and stable coronary artery plaque. The rupture of such plaques and the subsequent formation of thrombi are currently recognized as the primary mechanisms of heart attacks and strokes.

FluoroPharma intends to be a leader in the discovery, development, and commercialization of innovative and targeted molecular imaging pharmaceuticals that improve disease detection.

For more information, see the company website at www.FluoroPharma.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html